ArticleMolecular biology reports2026
SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAltered platinum chemotherapy sensitivity is a major determinant of treatment outcome in ovarian cancer; however, the molecular mechanisms underlying adaptive chemotherapy responses remain incompletely understood. Sphingomyelin synthase 1 (SMS1) and sphingomyelin synthase 2 (SMS2), key enzymes involved in sphingomyelin biosynthesis, have been implicated in cancer biology, but their roles in platinum chemotherapy response remain unclear. METHODS AND
resultsSMS1 and SMS2 expression was evaluated in ovarian cancer cells following chemotherapy exposure. Gain- and loss-of-function approaches were used to investigate their effects on cell proliferation, apoptosis, and chemotherapy sensitivity, while biochemical assays were performed to explore underlying mechanisms. Cisplatin selectively induced SMS1, but not SMS2, expression at both mRNA and protein levels in a dose- and time-dependent manner. Silencing of either SMS1 or SMS2 inhibited cell growth, promoted apoptosis, and enhanced sensitivity to cisplatin and paclitaxel. However, only SMS1 overexpression consistently protected cells against cisplatin- and paclitaxel-induced apoptosis. Mechanistically, SMS1 depletion caused lysosomal impairment, increased lipid peroxidation, and enhanced lysosome-associated oxidative injury, whereas SMS2 depletion induced oxidative stress-related alterations without a clearly defined dominant downstream mechanism. Importantly, multiple platinum agents, including cisplatin, carboplatin, and oxaliplatin, selectively induced SMS1 expression, and SMS1 depletion enhanced sensitivity to platinum-based chemotherapy. Clinical survival analysis further revealed that high SMS1 expression was associated with poorer outcomes, particularly in patients receiving Taxol plus platinum-based chemotherapy.
conclusionsSMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. SMS1 functions as a platinum-induced adaptive resistance factor by maintaining lysosomal homeostasis and supporting tumor cell survival. Disrupting SMS1-mediated adaptation may represent a potential strategy to enhance platinum chemotherapy efficacy. Although SMS2 contributes to chemotherapy response, its downstream mechanisms remain to be further elucidated.
Indexed as
Identifiers
42593674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.